Syntara Limited (ASX:SNT) Expands Skin Scarring Program with SNT-9465
Syntara Limited (ASX:SNT) expands its skin scarring program with the new SNT-9465 drug, initiating Phase 1a/b trials in 2025.
Category: ASX-SNT
Syntara Limited
Latest News
Prospech Limited (ASX:PRS) Reports High-Grade REE Assays at Korsnäs Project
Orthocell Limited (ASX:OCC) Receives Singapore Regulatory Approval for Striate+
Tower Limited (ASX:TWR) Announces NZ$45m Capital Return to Shareholders
Dropsuite Limited (ASX:DSE) Shareholding Update and Supports NinjaOne Transaction
Cygnus Metals Limited (ASX:CY5) Reports Strong Drilling Results at Chibougamau Project
RBR Group Limited (ASX:RBR) Announces Mozambique LNG Project Update
Larvotto Resources Limited (ASX:LRV) Acquires Echidna Gully to Support Hillgrove Mine
Kali Metals Limited (ASX:KM1) Expands Pilbara Gold Tenure
Firebird Metals Limited (ASX:FRB) Granted Mining Lease for Oakover Project
Dropsuite Limited (ASX:DSE) Faces Application to Takeovers Panel
The Hub of Australian Finance News